{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:02:59Z","timestamp":1766048579665,"version":"3.41.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004089","name":"Krembil Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004089","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003136","name":"Edmond J Safra Philanthropic Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003136","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000263","name":"Parkinson Society Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000263","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.neuropharm.2015.05.033","type":"journal-article","created":{"date-parts":[[2015,6,13]],"date-time":"2015-06-13T10:23:29Z","timestamp":1434191009000},"page":"306-311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["The highly-selective 5-HT1A agonist F15599 reduces l-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque"],"prefix":"10.1016","volume":"97","author":[{"given":"Philippe","family":"Huot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom H.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan H.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Newman-Tancredi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan M.","family":"Brotchie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2015.05.033_bib1","first-page":"1","article-title":"F15599, a highly selective post-synaptic 5-HT1A receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity","author":"Assie","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib2","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.1476-5381.1996.tb15749.x","article-title":"Possible in\u00a0vivo 5-HT reuptake blocking properties of 8-OH-DPAT assessed by measuring hippocampal extracellular 5-HT using microdialysis in rats","volume":"119","author":"Assie","year":"1996","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib3","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/sj.bjp.0703426","article-title":"[(3)H]-8-OH-DPAT binding in the rat brain raphe area: involvement of 5-HT(1A) and non-5-HT(1A) receptors","volume":"130","author":"Assie","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00702-003-0094-7","article-title":"Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile","volume":"111","author":"Bartoszyk","year":"2004","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib5","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/mds.25366","article-title":"Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia","volume":"28","author":"Bezard","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib6","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1212\/WNL.57.10.1829","article-title":"Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models","volume":"57","author":"Bibbiani","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2015.05.033_bib7","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2015.05.033_bib8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3389\/fneur.2014.00242","article-title":"Presynaptic mechanisms of l-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications","volume":"5","author":"Cenci","year":"2014","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib9","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0026-895X(25)11082-1","article-title":"Intrinsic activity of enantiomers of 8-hydroxy-2-(di-n-propylamino)tetralin and its analogs at 5-hydroxytryptamine1A receptors that are negatively coupled to adenylate cyclase","volume":"39","author":"Cornfield","year":"1991","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib10","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.euroneuro.2010.04.005","article-title":"F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists","volume":"20","author":"Depoortere","year":"2010","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib11","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.expneurol.2011.02.012","article-title":"Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats","volume":"229","author":"Dupre","year":"2011","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib12","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0028-3908(99)00033-7","article-title":"Modulation of 5-HT1A receptor signalling by point-mutation of cysteine351 in the rat Galpha(o) protein","volume":"38","author":"Dupuis","year":"1999","journal-title":"Neuropharmacology"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.neuropharm.2015.05.033_bib13","doi-asserted-by":"crossref","first-page":"S497","DOI":"10.1002\/mds.22028","article-title":"The history of dopamine and levodopa in the treatment of Parkinson's disease","volume":"23","author":"Fahn","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib14","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/mds.25133","article-title":"A\u00a0critique of available scales and presentation of the non-human primate dyskinesia rating scale","volume":"27","author":"Fox","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mds.21226","article-title":"Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial","volume":"22","author":"Goetz","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib16","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.parkreldis.2008.11.001","article-title":"Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys","volume":"15","author":"Gregoire","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib17","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0006-3223(90)90627-E","article-title":"Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites","volume":"28","author":"Hamik","year":"1990","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2015.05.033_bib18","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.20324","article-title":"Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years","volume":"20","author":"Hely","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejphar.2010.04.034","article-title":"Actions of the prototypical 5-HT1A receptor agonist 8-OH-DPAT at human alpha2-adrenoceptors: (+)8-OH-DPAT, but not (-)8-OH-DPAT is an alpha2B subtype preferential agonist","volume":"640","author":"Heusler","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2015.05.033_bib21","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1212\/WNL.57.8.1497","article-title":"Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease","volume":"57","author":"Hughes","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2015.05.033_bib22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.expneurol.2011.07.006","article-title":"5-HT(1A) receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: bridging the gap between serotonergic and glutamatergic mechanisms","volume":"231","author":"Huot","year":"2011","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib23","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00221-013-3621-2","article-title":"The serotonergic system in motor and non-motor manifestations of Parkinson's disease","volume":"230","author":"Huot","year":"2013","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.pneurobio.2011.08.004","article-title":"The serotonergic system in Parkinson's disease","volume":"95","author":"Huot","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.111.184093","article-title":"Anatomically-selective 5-HT1A and 5-HT2A therapies for Parkinson's disease \u2013 an approach to reducing dyskinesia without exacerbating parkinsonism?","volume":"339","author":"Huot","year":"2011","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib26","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1124\/jpet.112.195693","article-title":"L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease","volume":"342","author":"Huot","year":"2012","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib27","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.neuropharm.2012.06.012","article-title":"L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease","volume":"63","author":"Huot","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2015.05.033_bib28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/pr.111.005678","article-title":"The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease","volume":"65","author":"Huot","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib29","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1016\/j.neurobiolaging.2010.09.011","article-title":"Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque","volume":"33","author":"Huot","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2015.05.033_bib30","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/ejn.12093","article-title":"Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque","volume":"37","author":"Huot","year":"2013","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib31","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neuropharm.2015.01.012","article-title":"Activity of serotonin 5-HT receptor \u2018biased agonists\u2019 in rat models of Parkinson's disease and l-DOPA-induced dyskinesia","volume":"93C","author":"Iderberg","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2015.05.033_bib32","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1124\/jpet.106.110429","article-title":"In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\u2216 increased motor disability","volume":"319","author":"Iravani","year":"2006","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib33","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1124\/jpet.110.166629","article-title":"Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease","volume":"333","author":"Johnston","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib34","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1002\/mds.23172","article-title":"The alpha adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates","volume":"25","author":"Johnston","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neuropharm.2013.06.005","article-title":"TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque","volume":"73C","author":"Johnston","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2015.05.033_bib36","first-page":"133","article-title":"Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease","volume":"54","author":"Kannari","year":"2002","journal-title":"No To Shinkei"},{"key":"10.1016\/j.neuropharm.2015.05.033_bib37","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1046\/j.1471-4159.2001.00184.x","article-title":"Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation","volume":"76","author":"Kannari","year":"2001","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib38","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1124\/jpet.110.173948","article-title":"Functional selectivity and biased receptor signaling","volume":"336","author":"Kenakin","year":"2011","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib39","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.pnpbp.2012.12.008","article-title":"The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques","volume":"43","author":"Koprich","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2015.05.033_bib40","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1111\/j.1476-5381.2010.00738.x","article-title":"Preferential in\u00a0vivo action of F15599, a novel 5-HT(1A) receptor agonist, at postsynaptic 5-HT(1A) receptors","volume":"160","author":"Llado-Pelfort","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib41","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1021\/jm070714l","article-title":"High-efficacy 5-HT1A agonists for antidepressant treatment: a renewed opportunity","volume":"50","author":"Maurel","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1471-4159.2011.07292.x","article-title":"Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia","volume":"118","author":"Nevalainen","year":"2011","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib43","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2217\/npy.11.12","article-title":"Biased agonism at serotonin 5-HT1A receptors: preferential postsynaptic activity for improved therapy of CNS disorders","volume":"1","author":"Newman-Tancredi","year":"2011","journal-title":"Neuropsychiatry"},{"key":"10.1016\/j.neuropharm.2015.05.033_bib44","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1017\/S1461145704005000","article-title":"Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia","volume":"8","author":"Newman-Tancredi","year":"2005","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib45","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0028-3908(97)00022-1","article-title":"Agonist and inverse agonist efficacy at human recombinant serotonin 5-HT1A receptors as a function of receptor: G-protein stoichiometry","volume":"36","author":"Newman-Tancredi","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2015.05.033_bib46","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1476-5381.2008.00001.x","article-title":"Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist","volume":"156","author":"Newman-Tancredi","year":"2009","journal-title":"Br. J. Pharmacol."},{"year":"1996","series-title":"N.\u00a0Institute of Laboratory Animal Resources (U.S.). Committee on Care and Use of Laboratory Animals","author":"NIH","key":"10.1016\/j.neuropharm.2015.05.033_bib47"},{"key":"10.1016\/j.neuropharm.2015.05.033_bib48","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S0022-3565(25)38624-6","article-title":"Excitation of noradrenergic cell firing by 5-hydroxytryptamine1A agonists correlates with dopamine antagonist properties","volume":"268","author":"Piercey","year":"1994","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib49","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","article-title":"Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in adjunct therapy with rasagiline given once daily, study): a randomised, double-blind, parallel-group trial","volume":"365","author":"Rascol","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2015.05.033_bib50","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1515\/DMDI.1990.8.1-2.85","article-title":"Neurochemical profile of eltoprazine","volume":"8","author":"Schipper","year":"1990","journal-title":"Drug Metabol. Drug Interact."},{"key":"10.1016\/j.neuropharm.2015.05.033_bib51","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/brain\/awu409","article-title":"Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study","volume":"138","author":"Svenningsson","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2015.05.033_bib52","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1124\/jpet.108.144097","article-title":"Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques","volume":"328","author":"Visanji","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Ther."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390815002142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390815002142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T16:20:40Z","timestamp":1748449240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390815002142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":52,"alternative-id":["S0028390815002142"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2015.05.033","relation":{},"ISSN":["0028-3908"],"issn-type":[{"type":"print","value":"0028-3908"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The highly-selective 5-HT1A agonist F15599 reduces l-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2015.05.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}